The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
|Videos|March 14, 2011
Dr. Pearlstone on Biomarker Testing in the Community
Author(s)David Pearlstone, MD
David Pearlstone, MD, Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Biomarker Testing in the Community Setting
Advertisement
David Pearlstone, MD, Co-Division Chief, Breast Oncology from John Theurer Cancer Center, on Biomarker Testing in the Community Setting.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.
Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 10/4/2026
2
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
3
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
4
FDA Flashback: Hematologic Cancer Decisions and News From September 2026
5